Paul Ridker, MD
Cardiovascular Disease · Boston, MANPI 1063478261
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $471,032 of the $572,334 with a category attached, or 82.3%. It is spread thinly across 23 manufacturers, the largest accounting for just 14.6%. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $2192.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agepha Pharma FZ LLC$83K
- CSL Behring$60K
- Pfizer$56K
- AstraZeneca$55K
- Novo Nordisk AS$50K
- Amgen$46K
- plus $221K from 17 others
Across 50 payments — averaging $313,695 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$13.6M
- Amarin Pharma, Inc.$1.6M
- Pfizer$243K
- Esperion Therapeutics, Inc.$100K
- CSL Behring$62K
- Novo Nordisk AS$37K
- plus $2K from 2 others
What the payments were for
- Consulting fees$471,03282%
- Speaking & faculty fees$29,8315%
- Travel & lodging$66,90912%
- Food & beverage$4,4571%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agepha Pharma FZ LLC | 26 | $83,456 |
| CSL Behring | 36 | $60,093 |
| Pfizer | 17 | $56,397 |
| AstraZeneca | 33 | $54,769 |
| Novo Nordisk AS | 14 | $50,423 |
| Amgen(2 entities) | 16 | $46,188 |
| Eli Lilly | 48 | $41,412 |
| Amarin Pharma, Inc. | 17 | $34,979 |
| KOWA Company, LTD. | 11 | $19,149 |
| Janssen Research & Development, LLC | 4 | $16,733 |
| Astrazeneca UK Limited | 4 | $15,414 |
| GSK | 2 | $13,839 |
| Ardelyx, Inc. | 1 | $13,600 |
| Alnylam Pharmaceuticals Inc. | 2 | $13,118 |
| Merck | 6 | $11,223 |
| Sanofi Pasteur Inc. | 3 | $9,474 |
| Ipsen Bioscience Inc. | 1 | $9,405 |
| Heartflow, Inc. | 2 | $6,250 |
| Esperion Therapeutics, Inc. | 4 | $5,647 |
| Kowa Research Institute, Inc. | 3 | $5,214 |
| Novo Nordisk | 3 | $3,392 |
| Boehringer Ingelheim International GmbH | 1 | $1,500 |
| Astrazeneca AB | 7 | $662 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$572,334 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Ignacio Inglessis-AzuajeBoston$545K
- Jorge PlutzkyBoston$528K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.